Mesi-2

Metformin Hydrochloride / Sitagliptin, the active ingredient in Mesi-2, is a Biguanide / DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Mesi-2 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesi-2 is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Inadequate control on metformin alone: provides additional glucose reduction when added to existing therapy. - Combination therapy in adults: simplifies regimen and may improve medication adherence.

Mesi-2 may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when combined with insulin or sulfonylureas. - Metallic taste: transient alteration in taste perception. - Upper respiratory tract symptoms: nasopharyngitis or cough.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: can occur with concomitant insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Allergic reactions: rash, pruritus, or angio‑edema. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Renal impairment: worsening kidney function, particularly with metformin accumulation.

Before prescribing Mesi-2, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Renal function: assess baseline creatinine clearance and monitor periodically. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Hypoglycaemia monitoring: especially when used with insulin or sulfonylureas. - Pregnancy and lactation: consider only if benefits outweigh potential risks. - Vitamin B12 levels: monitor during long‑term metformin therapy. - Store at ambient temperature: keep in the original container, protect from moisture.

Mesi-2 can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Iodinated contrast agents in patients with renal impairment: may precipitate metformin‑associated lactic acidosis. - Other DPP‑4 inhibitors: additive pharmacologic effect, not recommended.

Moderate Interactions (Monitor Closely): - Cimetidine or other renal tubular secretion inhibitors: may raise metformin plasma concentrations. - Diuretics: can affect glucose control and electrolyte balance. - ACE inhibitors or ARBs: may increase risk of renal dysfunction when combined with metformin.